PRIOSOL CON 4 mmol/L POTASSIUM HEMOFILTRATION SOLUTION

Introduction

Package Leaflet: Information for the Patient

Priosol with 4 mmol/l of Potassium Solution for Hemofiltration

Read all of this leaflet carefully before this medicine is administered to you, because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Contents of the Package Leaflet

1. What Priosol with 4 mmol/l of Potassium is and what it is used for
2. What you need to know before you are given Priosol with 4 mmol/l of Potassium
3. How to use Priosol with 4 mmol/l of Potassium
4. Possible side effects
5. Storage of Priosol with 4 mmol/l of Potassium
6. Contents of the pack and other information

1. What Priosol with 4 mmol/l of Potassium is and what it is used for

Priosol with 4 mmol/l of Potassium is a solution for hemofiltration. It is used in patients with acute renal failure, when the kidneys are not able to remove waste products from the blood. Continuous hemofiltration is a procedure used to remove waste products from the body, which are normally excreted in the urine through the kidneys. The solution corrects the balance of fluids and ensures that after treatment, the loss of salts (electrolytes) is restored.

2. What you need to know before you are given Priosol with 4 mmol/l of Potassium

Priosol with 4 mmol/l of Potassium should not be administered if:

• you have an abnormally high level of potassium in your blood (hyperkalemia)
• your blood contains abnormally low levels of acidic substances (metabolic alkalosis)

The hemofiltration procedure should not be used if you have

• renal failure along with a very high metabolic turnover (hypercatabolic state), in this situation the accumulation of waste products in your body can no longer be corrected by hemofiltration
• poor blood flow at the site of insertion of the catheter in the vein
• a high risk of bleeding due to receiving medications to prevent blood clotting (systemic anticoagulation)

Warnings and precautions

Consult your doctor or pharmacist before you are given Priosol with 4 mmol/l of Potassium.

Before and during hemofiltration, your blood pressure and fluid balance, salts (electrolytes), acid-base balance, and kidney function will be monitored. Your blood sugar and phosphate levels will be regularly checked.

In addition, your serum potassium concentrations will be monitored before and during hemofiltration.

Using Priosol with 4 mmol/l of Potassium with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

The level of other medicines in your blood may be reduced during hemofiltration, which your doctor will take into account.

Interactions with other medicines can be avoided with the use of the correct dose of the hemofiltration solution and careful monitoring.

The following interactions will be considered:

• Infusions administered in intensive care may change the composition of the blood and its water status.
• The toxic effects of certain medicines used to treat heart failure (medicines containing digitalis) may not become apparent if your potassium or magnesium levels are too high, or your calcium levels are too low. When these levels are corrected by hemofiltration, these toxic effects may appear and cause, for example, heart rhythm abnormalities. If you have low potassium or high calcium levels in your blood, digitalis may produce toxic effects at doses lower than those normally used for treatment.
• Vitamin D and medicines containing calcium may increase the risk of elevated calcium levels in the blood (hypercalcemia).
• The use of additional sodium hydrogen carbonate may increase the risk of low acid levels in the blood (metabolic alkalosis).

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before you are given this medicine.

There are currently no sufficient data on the use of hemofiltration solutions during pregnancy. However, since all components of this medicine are natural substances that only replace the same substances that disappear from the body during hemofiltration, no risks are expected for the child during pregnancy and breastfeeding, nor any effects on fertility.

Driving and using machines

This medicine is usually administered to patients who are immobilized in a hospital or dialysis unit, which excludes driving and using machines.

3. How to use Priosol with 4 mmol/l of Potassium

This medicine will only be administered to you under the direction of a doctor with experience in hemofiltration techniques.

Your doctor will decide the appropriate dose for you, taking into account your clinical condition, body weight, and metabolic state. Unless otherwise indicated, in patients of any age, a filtration rate of 20-25 ml/kg of body weight per hour is recommended for the elimination of substances that are normally excreted in the urine.

The hemofiltration solution will be administered to you via the tube system of the hemofiltration equipment (extracorporeal circulation) using a perfusion pump.

Treatment of acute renal failure is carried out for a limited period and ends when kidney function is fully restored.

If you are given more Priosol with 4 mmol/l of Potassium than recommended

No life-threatening situations have been described after administration of the prescribed dose of this medicine. Administration can be stopped immediately if necessary.

Unbalanced administration may lead to an excess or deficit of fluid in the body (hyperhydration or dehydration). This situation becomes apparent through changes in blood pressure or pulse.

If too much of the hemofiltration solution is administered, an overdose of hydrogen carbonate may occur. This may result in abnormally low acid levels in the blood (metabolic alkalosis), a lower amount of dissolved calcium in the blood (decrease in ionized calcium), or muscle cramps (tetany).

An overdose can cause heart failure and/or pulmonary congestion and may disrupt the acid-base and electrolyte balance.

Your doctor will decide on the appropriate treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

No cases of side effects associated with this medicine have been described to date. However, the following side effects may occur. The frequency of these side effects cannot be estimated from the available data:

Excess or deficit of fluid in the body (hyperhydration or dehydration), abnormal levels of salts (electrolytes) - for example, too much potassium in the blood (hyperkalemia) - low phosphate levels in the blood (hypophosphatemia), high sugar levels in the blood (hyperglycemia), abnormally low acid levels in the blood (metabolic alkalosis), high or low blood pressure (hypertension or hypotension), nausea, vomiting, and muscle cramps.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Annex V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Priosol with 4 mmol/l of Potassium

Keep this medicine out of the sight and reach of children.

Do not administer this medicine after the expiry date stated on the bag and carton after "EXP". The expiry date is the last day of the month stated.

Storage conditions

Do not store above 25°C.

Do not refrigerate or freeze.

Storage conditions after preparation of the ready-to-use solution

The mixed product should be used immediately. The mixed product is physically and chemically stable for 24 hours at 25°C.

Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the pharmacy's SIGRE collection point. If you are unsure, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Contents of the pack and other information

Composition of Priosol with 4 mmol/l of Potassium

Composition of the ready-to-use hemofiltration solution after mixing:

1,000 ml of the ready-to-use hemofiltration solution contain [mmol/l]:

Na+ 140

K+4.0

Ca2+ 1.5

Mg2+ 0.5

Cl- 113

HCO3- 35.0

Anhydrous glucose 5.6 (equiv. to 1.0 g)

Theoretical osmolality [mOsm/l] 300

pH 7.0-8.0

Other components are:

Electrolyte solution (small chamber)

Hydrochloric acid 25% (for pH adjustment), water for injections

Bicarbonate solution (large chamber)

Carbon dioxide (for pH adjustment), water for injections

Appearance of the product and pack contents

Hemofiltration solution.

Clear and colorless solution, free from visible particles.

This medicine is provided in a two-chamber bag. When the two solutions are mixed by opening the seal between the two chambers, the ready-to-use hemofiltration solution is obtained.

Two bags of 5,000 ml (two-chamber bags, 4,445 ml and 555 ml) per carton.

Marketing authorization holder and manufacturer

Marketing authorization holder

• Braun Avitum AG

Schwarzenberger Weg 73-79

34212 Melsungen

Germany

Manufacturer

• Braun Avitum AG

Kattenvenner Str. 32

49219 Glandorf

Germany

This medicine is authorized in the Member States of the European Economic Area under the following names:

Austria, Germany, Luxembourg: Duosol mit 4 mmol/l Kalium Hämofiltrationslösung

Bulgaria: ?????? 4 mmol/l ?????, ??????? ?? ?????????????

Croatia: Duosol s 4 mmol/l kalija otopina za hemofiltraciju

Czech Republic: Duosol s 4 mmol/l kalia

Denmark, Norway, Sweden: Duosol Kalium 4 mmol/l

Greece: Duosol with 4 mmol/l Potassium Δι?λυμα αιμοδι?θησης

Estonia: Duosol koos 4 mmol/l kaaliumiga, hemofiltratsioonilahus

Finland: Duosol cum 4 mmol/l Kalium hemofiltraationeste

France: Subsol avec 4 mmol/l potassium, solution pour hémofiltration hémodialyse et hémodiafiltration

Hungary: Nefrosol 4 mmol/l kálium hemofiltrációs oldat

Ireland: Nefrosol with 4 mmol/l Potassium solution for haemofiltration

Italy: Duosol con 4 mmol/l di potassio soluzione per emofiltrazione

Latvia: Duosol ar 4 mmol/l kalija škidums hemofiltracijai

Lithuania: Duosol K 4 hemofiltracijos tirpalas

Poland: Duosol zawierajacy 4 mmol/l potasu

Portugal: Duosol com potássio 4 mmol/l, solução para hemofiltração

Romania: Nefrosol cu 4 mmol/l potasiu, solutie pentru hemofiltrare

Slovenia: Duosol s 4 mmol/l kalija raztopina za hemofiltracijo

Spain: Priosol con 4 mmol/l de Potasio solución para hemofiltración

Netherlands: Duosol met 4 mmol/l Kalium, oplossing voor hemofiltratie

United Kingdom: Duosol with 4 mmol/l Potassium solution for haemofiltration

Date of last revision of this leaflet: September 2018

--------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Instructions for preparation of the ready-to-use hemofiltration solution

The packaging and solution should be visually inspected before use. The hemofiltration solutions should only be used if the packaging (outer wrapping and two-chamber bag), the peel seal, and the connectors are not damaged and are intact, and if the solution is clear and colorless and free from visible particles.

Remove the outer wrapping only immediately before use.

Administration of the ready-to-use hemofiltration solution

The hemofiltration solution should be warmed to approximately body temperature using an integrated or external warmer. The solution should not be perfused under any circumstances if it is below ambient temperature.

During the application of this medicine, precipitation of calcium carbonate in the tubes has been observed in rare cases, particularly near the pump unit and the heating unit. Therefore, during hemofiltration, the tubes should be visually inspected every 30 minutes to ensure that the solution in the tube system is clear and free from precipitates. Precipitation may also occur with a considerable delay after starting treatment. If precipitates are observed, the tubes should be replaced immediately and the patient should be closely monitored.

For single use only. Any remaining fraction of the solution and any damaged packaging should be discarded.